arrow
B

Bruno Coudert

centre national de la recherche scientifique (cnrs)
H指数:59
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic stratification ability of the CPS plus EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
2024-05-012
OA
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy

新辅助化疗治疗HER2-low和HER2-zero早期乳腺癌的病理完全缓解和生存

2023-08-108
OAAI
Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study
2022-04-012
OAAI
Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study
2021-05-0113
OAAI
Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)
2020-12-231
OAAI
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study
2020-11-016
OAAI
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real -life ESME metastatic breast cancer cohort
BREAST
IF7.9
2020-08-0128
OAAI
Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study
2020-05-2081
OA
Prediction of PFS and OS under third and fourth line chemotherapy among metastatic triple-negative breast cancer patients in the national multicenter ESME metastatic breast cancer cohort
2020-02-150
PRE
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy (vol 119, pg 950, 2018)
2019-06-247
OAAI
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics

在转移性三阴性乳腺癌患者中,每周或每周两次使用Iniparib联合吉西他滨/卡铂: 一项具有药代动力学的II期随机开放标签研究

2019-06-0614
PREAI
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

帕妥珠单抗联合曲妥珠单抗和紫杉烷一线治疗HER2-positive局部复发或转移性乳腺癌的初步安全性和有效性 (PERUSE)

2019-05-0189
OAAI